Drugs commonly used clinically for treating type 2 diabetes can also reduce PAI-1, a phenomenon primarily associated with lower insulin precursors and improved insulin resistance, expanding the evidence for the clinical use of these drugs. This evidence concerns the gene SERPINE1 and type 2 diabetes mellitus.